Physician profile
Steven Saunders
NPI 1528157849
$591.67
in general payments reported to CMS, 2019-2025
12 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.03 · 2022: $34.95 · 2023: $78.59 · 2024: $339 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $169.93 | 2023-2025 | Jardiance |
| Stryker Corporation | $133.03 | 2024 | Mako |
| Depuy Synthes Sales INC. | $66.34 | 2024-2025 | Orthovisc, Monovisc |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.53 | 2023-2025 | Jardiance |
| Dexcom, INC. | $38.79 | 2022-2024 | Dexcom G6 Transmitter |
| Orthofix Medical, INC. | $29.58 | 2024-2025 | Physio-Stim, Accelstim |
| Teva Pharmaceuticals USA, INC. | $22.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.00 | 2021 | |
| Abbvie INC. | $18.16 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.16 | 2024 | Euflexxa |
| Novo Nordisk INC | $16.03 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.57 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.